Ionis Pharmaceuticals IONS Tryngolza — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's tryngolza — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's tryngolza — revenue?
- Ionis Pharmaceuticals (IONS) reported tryngolza — revenue of $27.1M in Q1 2026.
- How has Ionis Pharmaceuticals's tryngolza — revenue changed year-over-year?
- Ionis Pharmaceuticals's tryngolza — revenue increased by 331.0% year-over-year, from $6.29M to $27.1M.
- What does tryngolza — revenue mean?
- The total net sales generated from the Tryngolza product after excluding taxes.
- How do you interpret tryngolza — revenue?
- An increase indicates growing market demand, successful commercial execution, or expanded patient access for the drug, while a decrease may signal competitive pressure, market saturation, or supply chain challenges.
- How does tryngolza — revenue compare across companies?
- This is comparable to product-specific net revenue metrics reported by other biopharmaceutical companies for their commercialized assets, often categorized under product sales or net product revenue.